New Lifetime High Reached By NuVasive (NUVA)
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified NuVasive as such a stock due to the following factors:
- NUVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $36.0 million.
- NUVA has traded 19,247 shares today.
- NUVA is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in NUVA with the Ticky from Trade-Ideas. See the FREE profile for NUVA NOW at Trade-Ideas
More details on NUVA:
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. NUVA has a PE ratio of 129. Currently there are 12 analysts that rate NuVasive a buy, no analysts rate it a sell, and 2 rate it a hold.
The average volume for NuVasive has been 708,900 shares per day over the past 30 days. NuVasive has a market cap of $3.0 billion and is part of the health care sector and health services industry. The stock has a beta of 0.71 and a short float of 8% with 6.07 days to cover. Shares are up 13.8% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates NuVasive as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.
Highlights from the ratings report include:
- NUVA's revenue growth has slightly outpaced the industry average of 7.9%. Since the same quarter one year prior, revenues rose by 11.8%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Net operating cash flow has significantly increased by 120.54% to $57.39 million when compared to the same quarter last year. In addition, NUVASIVE INC has also vastly surpassed the industry average cash flow growth rate of -11.82%.
- NUVASIVE INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, NUVASIVE INC turned its bottom line around by earning $1.27 versus -$0.38 in the prior year. This year, the market expects an improvement in earnings ($1.51 versus $1.27).
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. When compared to other companies in the Health Care Equipment & Supplies industry and the overall market, NUVASIVE INC's return on equity is below that of both the industry average and the S&P 500.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 128.2% when compared to the same quarter one year ago, falling from $31.56 million to -$8.89 million.
- You can view the full NuVasive Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.